A 6-month 100% online academic experience with the most advanced syllabus in MDS, Myeloproliferative Neoplasms and CLL”

In recent years there has been an important evolution in the field of oncohematology as a result of the of Oncohematology as a result of continuous work in the scientific field. A work that has that has made it possible to understand the etiology of myelodysplastic syndromes and to develop new drugs according to the risk and progression of the disease.

A scenario that leads medical professionals to be in a continuous updating of their knowledge in both diagnostic and therapeutic procedures. In this line, TECH has decided to create this Postgraduate diploma of 6 months of duration with the most advanced syllabus, elaborated by real specialists in this area.

It is a program with a theoretical-practical approach that will allow the graduate to be up to date in the management of low and high risk MDS, the results with hypomethylating agents and with HSCT, as well as Chronic Lymphocytic Leukemia with the advantages and disadvantages of the different therapeutic alternatives.  In addition, thanks to the multimedia pills and the numerous pedagogical material, the graduate will delve into Myeloproliferative Neoplasms and their difficult differential diagnosis.

Likewise, the Relearning method will lead the professional to consolidate the most important concepts in a simple way, reducing concepts in a simple way, thus reducing the long hours of study and memorization of study and memorization.

Thus, the physician is faced with a first class academic experience that adapts  to their needs for updating and their daily activities. And the fact is that, without the need to attend centers in person, or have classes with fixed schedules, the graduate will be able to better self-manage access to this university program.  

A university degree adapted to your needs. Flexible and with content easily accessible from your digital device with internet connection”

This Postgraduate diploma in Myelodysplastic Syndromes and Chronic Leukemia contains the most complete and up-to-date scientific program on the market. The most important features include:

• The development of practical cases presented by experts in Hematology and Hemotherapy
• The graphic, schematic, and practical contents which provide scientific and practical information on the disciplines that are essential for professional practice
• Practical exercises where the self-assessment process can be carried out to improve learning
• Its special emphasis on innovative methodologies
• Theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection work
• Content that is accessible from any fixed or portable device with an Internet connection

Delve whenever you wish into the latest therapeutic advances in Myeloproliferative Neoplasms through the syllabus prepared by distinguished specialists in Oncohematology”

The program's teaching staff includes professionals from the sector who bring to this program the experience of their work, in addition to recognized specialists from prestigious reference societies and universities.

The multimedia content, developed with the latest educational technology, will provide professionals with situated and contextual learning, i.e., a simulated environment that will provide immersive training, designed for training oneself in real situations.

The design of this program focuses on Problem-Based Learning, by means of which the professional must try to solve the different professional practice situations that are presented throughout the academic course. For this , purpose students will be assisted by an innovative interactive video system developed by renowned experts.

With this university degree you will be aware of the clinical development of promising new drugs for high-risk MDS”

The multiple didactic resources of this degree will facilitate your update in Myelodysplastic Syndromes and Chronic Leukemia”

The syllabus of this Postgraduate diploma provides a current vision on Myelodysplastic Syndromes and Chronic Leukemia, both from its present approach and the existing pharmacological trials. A wide field of action that will lead the graduate to update an update on the differential diagnosis of CML, the latest existing therapeutic alternatives or the most effective complementary tests in patients with Chronic Lymphocytic Leukemia. All this, in addition to a Virtual Library, accessible 24 hours a day, from any digital device with internet connection.

A study plan that allows you to update and face the future challenge of dealing with the main chronic myeloproliferative neoplasms”

Module 1. Myelodysplastic Syndromes

1.1. General Aspects

1.1.1. Pathogenesis. CHIP, CCUS, ICUS
1.1.2. Epidemiology. Clinical Symptoms
1.1.3. Novo SMD vs. Secondary to treatment

1.2. Diagnostic

1.2.1. Cytology
1.2.2. Genetic and molecular alterations
1.2.3. Flow Cytometry

1.3. Classification. MDS/NMP

1.3.1. WHO
1.3.2. Chronic Heart Failure (CHF)
1.3.3. MDS/NMP

1.4. Prognostic indices

1.4.1. IPSS
1.4.2. IPSS-R
1.4.3. Molecular IPSS

1.5. Management of low-risk MDS

1.5.1. Use of erythropoietic stimulants
1.5.2. Iron chelating agents
1.5.3. MDS del(5q). Lenalidomide
1.5.4. Hypoplastic MDS

1.6. New medications in low-risk MDS

1.6.1. Luspatercept
1.6.2. Pharmaceuticals under development

1.7. Treatment of High-risk MDS

1.7.1. Hypomethylating agents
1.7.2. Intensive chemotherapy

1.8. New Drugs in SMD

1.8.1. Venetoclax plus hypomethylating agents
1.8.2. IDH1/IDH2 Inhibitors, Imetelstat and others

1.9. TPH in SMD

1.9.1. Indications
1.9.2. Modalities and conditioning

1.10. Role of comorbidities and geriatric assessment

1.10.1. Comorbidity scales
1.10.2. Quality of life Assessment
1.10.3. Patient-reported outcomes

Module 2. Chronic myeloproliferative neoplasms

2.1. Chronic Myeloid Leukemia. Diagnosis and clinical

2.1.1. Introduction. Epidemiology
2.1.2. Pathogenesis Diagnostic
2.1.3. Prognosis

2.2. LMC, Differential Diagnosis

2.2.1. Leukemoid reaction
2.2.2. LMMC
2.2.3. Atypical CML, CNL and others

2.3. CML. Treatment

2.3.1. Tirosin Kinasa Inhibitor. Imatinib
2.3.2. Second-generation TKi. Nilotinib. Dasatinib. Bosutinib
2.3.3. Other TKIs: Ponatinib. Asciminib
2.3.4. Other treatments TPH Role

2.4. Polycythemia Vera

2.4.1. Diagnosis and clinical
2.4.2. Criterios OMS. Differential Diagnosis
2.4.3. Prognosis. Low Risk Adated Treatment

2.5. High-risk polycythemia Vera, treatment

2.5.1. Initial cytoreduction options
2.5.2. Rescue options
2.5.3. Pregnancy Transformation

2.6. Essential Thrombocythemia

2.6.1. Diagnosis and clinical
2.6.2. WHO Criteria
2.6.3. Differential Diagnosis

2.7. Essential Thrombocythemia: prognosis and treatment

2.7.1. Prognosis
2.7.2. Cytoreduction indications
2.7.3. Hydroxyurea vs Anagrelide

2.8. Primary Myelofibrosis

2.8.1. Clinical Pathogenesis
2.8.2. Diagnosis. WHO Criteria
2.8.3. Prognosis Scales

2.9. Myelofibrosis Treatment

2.9.1. Anemia management
2.9.2. JAK Inhibitors
2.9.3. New Drugs in Myelofibrosis

2.10. TPH in Myelofibrosis

2.10.1. TPH candidate selection
2.10.2. MF conditioning

Module 3. Chronic Lymphocytic Leukemia

3.1. Diagnostic

3.1.1. Etiopathogenesis
3.1.2. Complementary Tests
3.1.3. Treatment Indications

3.2. Prognosis

3.2.1. Prognostic Factors and predictive
3.2.2. Prognostic indices

3.3. Role of comorbidities and geriatric Assessment

3.3.1. Comorbidity scales
3.3.2. Geriatric Scores
3.3.3. Quality of life questionnaires. PROMs

3.4. First-Line Treatment

3.4.1. Immunochemotherapy
3.4.2. BTK Inhibitors
3.4.3. Bcl2 inhibitor. Combinations

3.5. Relapse/refractory treatment

3.5.1. Algorithms
3.5.2. Treatment sequencing
3.5.3. Role of TPH in CLL

3.6. Practical handling of BTKi

3.6.1. Hemorrhagic complications
3.6.2. Cardiovascular Complications
3.6.3. Other toxicities

3.7. Practical handling of Venetoclax

3.7.1. SLT risk assessment and prophylaxis
3.7.2. Cytopenias management

3.8. COVID and LLC

3.8.1. Antivirals Treatment Indications
3.8.2. Pre-exposure prophylaxis indications
3.8.3. Other recommendations and vaccinations in CLL

3.9. Richter's syndrome

3.9.1. Pathogenesis and clinical
3.9.2. LDCG and LH. Clonal relation
3.9.3. Treatment Options

3.10. New Drugs in LLC

3.10.1. New BTKi
3.10.2. Other drugs under development
3.10.3. CAR T at LLC

Delves through the most recent scientific studies on the clonal relationship between LDCG and LH”